Video

Dr. Orellana-Noia on the Patient Population of the POLARIX Trial in DLBCL

Victor M. Orellana-Noia, MD, discusses the patient population of the phase 3 POLARIX trial in diffuse large B-cell lymphoma.

Victor M. Orellana-Noia, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the patient population of the phase 3 POLARIX trial (NCT03274492) in diffuse large B-cell lymphoma (DLBCL).

The POLARIX trial randomly assigned patients to receive polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP), or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated DLBCL.

Many phase 3 trials evaluating patients with DLBCL have a selection bias, including the POLARIX trial, Orellana-Noia says. The trial did not permit patients with transformed disease from indolent lymphoma or chronic lymphocytic leukemia, Orellana-Noia notes, adding that patients who had a prior solid organ transplant, had an HIV infection, or had central nervous system disease were not included.

Patients who experienced a statistical benefit from polatuzumab vedotin plus R-CHP included older patients who received full-dose, anthracycline-based therapy, plus those with stage III/IV non-bulky disease, Orellana-Noia continues.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma